Close Menu
  • Home
  • Technology
  • Devices
  • Business
  • Science
  • Gadgets
  • Startups
Ayaksız
  • Home
  • Technology

    Lucid and Bolt Plan 25,000 Robotaxis for Europe

    Eylül 18, 2026

    AMD Gives PC Builders More Choice With New Ryzen 5 Desktop Chips

    Eylül 11, 2026

    Apple Expands Device Protection With a $49.99 Family Plan

    Eylül 11, 2026

    Snapdragon 8 Elite Extreme Gen 6 Reportedly Beats MediaTek’s Next Flagship Chipset

    Eylül 11, 2026

    Pinterest CFO Julia Donnelly to Step Down in October

    Ağustos 30, 2026
  • Devices

    Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone

    Kasım 18, 2026

    Router Mode or Access Point Mode? Give Each Network Device a Clear Job

    Kasım 18, 2026

    Scanner Feeder or Glass? Choose According to the Original

    Kasım 13, 2026

    Borderless Printing: Why the Edges of Your Photo Can Disappear

    Kasım 12, 2026

    Camera AE Lock: Recompose a Scene Without Letting Exposure Drift

    Kasım 11, 2026
  • Business

    Google Pixel 11 Pro Leaked Renders Indicate It Might Sport Thinner Bezels Than the Pixel 10 Pro

    Mart 30, 2026

    Motorola Edge 70 Debuts With Snapdragon 7 Gen 4, Ultra-Slim 5.99mm Body

    Kasım 5, 2025

    Samsung Galaxy S26 Series Could See Price Increase Amid Rising Component Costs: Report

    Kasım 4, 2025

    Amazon’s AWS Partners with NBA to Power New AI Basketball Platform

    Ekim 4, 2025

    Billionaire-Backed Bitcoin Firm OranjeBTC to List on Brazil’s B3 Exchange

    Ekim 4, 2025
  • Science

    Double Rainbows: Why the Outer Arc Reverses Its Colors

    Kasım 18, 2026

    Why Ice Floats—and Why Water Behaves Differently Near Freezing

    Kasım 13, 2026

    Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

    Kasım 12, 2026

    A Light-Year Measures Distance: Understanding the Scale Behind Space Headlines

    Kasım 11, 2026

    Why the Sky Is Blue—and Why the Same Atmosphere Produces Red Sunsets

    Kasım 10, 2026
  • Gadgets

    Tripod Center Columns: Extra Height Comes with a Stability Tradeoff

    Kasım 18, 2026

    E Ink Ghosting: Match the Refresh Mode to the Task

    Kasım 13, 2026

    Camera Lens Hoods: Choose the Right Shape and Check the Whole Frame

    Kasım 12, 2026

    Pop Filters and Windscreens: Match Microphone Protection to the Noise

    Kasım 12, 2026

    USB Hub Power: Check Where Your Connected Devices Get Their Energy

    Kasım 11, 2026
  • Startups

    Cache-Control for Startups: No-Cache and No-Store Solve Different Problems

    Kasım 18, 2026

    Dead-Letter Queues: Investigate Before Replaying Failed Messages

    Kasım 13, 2026

    Database Connection Pools: Budget Across Every Application Replica

    Kasım 13, 2026

    Startup Staging Sites: Separate Search Visibility from Access Control

    Kasım 12, 2026

    API Idempotency Keys: Keep a Retry Connected to the Original Operation

    Kasım 11, 2026
Ayaksız
Anasayfa » Blog » Novo Nordisk Raises Alarm Over Deaths Linked to Compounded Versions of Weight-Loss Drug Wegovy
Business

Novo Nordisk Raises Alarm Over Deaths Linked to Compounded Versions of Weight-Loss Drug Wegovy

By ayaksızKasım 6, 2024Yorum yapılmamış3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Novo Nordisk recently acknowledged reports indicating that 10 people have died and over 100 have been hospitalized after using compounded versions of its popular weight-loss and diabetes drugs, Wegovy and Ozempic, chemically known as semaglutide. The company’s CFO, Karsten Munk Knudsen, confirmed awareness of these cases, which emerged from the FDA’s adverse events database. The database does not establish direct causality between compounded semaglutide and the deaths but serves as a preliminary warning mechanism for potential health risks.

The U.S. allows compounding pharmacies to create alternatives to brand-name drugs that are temporarily in short supply, achieved by mixing or altering drug ingredients. Until recently, Novo Nordisk’s semaglutide drugs, Wegovy and Ozempic, were on the FDA’s shortage list due to high demand, especially within the United States. This shortage situation permitted compounding pharmacies to manufacture copies.

When asked to elaborate, a Novo Nordisk spokesperson directed attention to the FDA’s adverse events database, which has recorded 10 deaths linked to compounded semaglutide over the past two years, though none identified a direct cause. The adverse event reports are submitted by doctors, patients, and drug manufacturers and are intended as preliminary safety signals rather than concrete scientific evidence. Reports often lack detailed information and may include multiple entries for the same incident, making it challenging to draw definitive conclusions.

Novo Nordisk CEO Lars Fruergaard Jorgensen expressed concern about the potential lack of regulatory oversight on compounded versions of these medications, especially given the FDA’s stringent surveillance of Novo Nordisk’s official products. He criticized the sale of compounded semaglutide variants online and in “health spas,” bypassing the formal supply chain used by Novo Nordisk and its competitor Eli Lilly for distributing their FDA-approved medications. “It beats me,” Jorgensen remarked, emphasizing the potential risks posed by unregulated products.

In October, Novo Nordisk requested that the FDA restrict compounding pharmacies from producing copycat versions of Wegovy and Ozempic, arguing that the complexities involved in manufacturing these drugs might exceed the capabilities of some compounders, leading to safety concerns. Knudsen added that Novo Nordisk had observed multiple safety issues with some compounded products, reinforcing the need for stricter regulatory measures.

Despite Novo Nordisk’s efforts to meet demand, Wegovy and Ozempic remain listed on the FDA’s shortages list, though all dose strengths are currently noted as available. Knudsen highlighted the significant investments made to expand production capacity and the ongoing dialogue with the FDA, expressing optimism that these drugs may eventually be removed from the shortage list, which could limit compounding pharmacies’ ability to create alternatives.

 

Compounded Drugs Drug Shortage FDA Novo Nordisk Ozempic Safety Concerns Semaglutide U.S. Health Regulations Wegovy
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
ayaksız
  • Website

Related Posts

Fiserv and Major Fuel Retailers Warn U.S. Stores Over Illegal Vape Sales

Temmuz 6, 2026

Google Pixel 11 Pro Leaked Renders Indicate It Might Sport Thinner Bezels Than the Pixel 10 Pro

Mart 30, 2026

Neuralink Plans High-Volume Brain Implant Production by 2026, Musk Says

Ocak 2, 2026
Add A Comment

Comments are closed.

Recent Posts
  • Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone
  • Cache-Control for Startups: No-Cache and No-Store Solve Different Problems
  • Tripod Center Columns: Extra Height Comes with a Stability Tradeoff
  • Double Rainbows: Why the Outer Arc Reverses Its Colors
  • Router Mode or Access Point Mode? Give Each Network Device a Clear Job
Tags
AI AI Chips AI Infrastructure Amazon Android Apple Artificial Intelligence Bitcoin ChatGPT China Cryptocurrency Cybersecurity data centers DeepSeek Donald Trump Electric Vehicles Elon Musk Ether Generative AI Google Huawei India Investment Iphone Meta Microsoft NASA National Security Nvidia OnePlus OpenAI Oppo Realme Samsung semiconductor industry Social media Sony SpaceX Technology Tesla Tether TikTok Vivo WhatsApp Xiaomi
Ayaksız
Instagram
© 2026 Ayaksız.

Type above and press Enter to search. Press Esc to cancel.